$QCLS

Q/C Technologies, Inc. Announces Dismissal of Stephano Slack LLC as Independent Auditor in March 2026 8-K Filing

Q/C Technologies, Inc. (NASDAQ: QCLS) has announced the dismissal of Stephano Slack LLC as its independent registered public accounting firm and the appointment of Grassi & Co., CPAs, P.C. effective March 9, 2026. This change follows a "going concern" warning included in Stephano Slack's report for 2023 and 2024, indicating substantial doubt about the company's ability to continue operations. Investors are advised to monitor future filings for financial reporting changes and the company's efforts to address its financial challenges.

Original reporting
Published Mar 14, 2026, 9:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 14, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Q/C Technologies, Inc. Announces Dismissal of Stephano Slack LLC as Independent Auditor in March 2026 8-K Filing — source image
Decision brief

The 30-second read

$QCLSBearishMed
01

Why it matters

The auditor dismissal and warning increase uncertainty, likely leading to a negative impact on stock performance in the short term.

02

Market read

The news is highly relevant for traders holding or considering trading QCLS shares, especially given the recent auditor change and financial warnings.

03

What to watch

Possible strategic restructuring or asset sales not yet disclosed could stabilize the company in the long run.

Timing: Immediate, as the news is recent and relevant for current trading sessions.

Background

QCLS's recent financial reports indicated liquidity concerns, and the auditor change follows a 'going concern' warning from Stephano Slack LLC.

Company-level read

Ticker impact

$QCLSBearishHigh confidence
Context

The news directly pertains to Q/C Technologies, Inc. (QCLS), highlighting significant corporate governance and financial concerns.

Expected impact

Potential short-term decline of 10-15% due to increased uncertainty and investor concern.

Evidence & confidence

The auditor change combined with 'going concern' warnings signals serious financial issues, likely leading to investor sell-off.

Market effects

Potential negative sentiment spreading to the finance and auditing sectors within the NASDAQ index.

Limited, as the news pertains specifically to a US-based company.

Negligible, unless similar issues are observed in comparable international firms.

Counterpoint

The company might be implementing corrective measures, and the stock could be oversold in the short term, presenting a potential buying opportunity for contrarian investors.

Key entities

  • Q/C Technologies, Inc.

    A NASDAQ-listed technology firm facing financial challenges.

  • Stephano Slack LLC

    The previous independent auditor dismissed due to 'going concern' warnings.

  • Grassi & Co., CPAs, P.C.

    The newly appointed independent auditor as of March 9, 2026.

Related articles

$BMRNMed

BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis

BioMarin (BMRN) shares rose 5% after settling a global patent dispute with Ascendis (ASND) over Yuviwel, an achondroplasia drug. Ascendis will pay BioMarin royalties of 20% of US net sales and 18% internationally until 2030. The settlement resolves pending litigation, including a US ITC investigation. Both companies framed the outcome positively, highlighting long-term benefits and commercial flexibility.

$ORAMedAI 8/10

Why Ormat Technologies Stock Could Be a Geothermal Powerhouse

Ormat Technologies (ORA) reported Q2 revenue growth of 10.6% YoY to $258.8M, with energy-storage revenue up 195% YoY. Google (GOOG) agreed to use Ormat's geothermal energy for AI data centers. Ormat is developing enhanced geothermal systems (EGS) with Pentagon interest. The company expects $1.15B-$1.2B revenue in 2026, with a low EV/EBITDA ratio of 16.6x.

$MDCXHighAI 8/10

Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI

Medicus Pharma (MDCX) reported progress in its SkinJect program, confirming a 200-microgram patch dose for further studies. The company is focusing on Gorlin syndrome and seeking a partner for nodular basal cell carcinoma. A potential partnership could bring $25,000+ in reimbursement. Additionally, MDCX is collaborating with Pfizer on a CD228-targeted antibody-drug conjugate for melanoma and solid tumors, receiving $2M in funding.